Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer

Tumori

Volumn 96, Issue 6, 2010, Pages 918-925

  Nicoletto, Maria Ornella ^a   Palma, Maurizia Dalla ^a   Donach, Martin E ^b   Gusella, Milena ^c   Cappetta, Alessandro ^a   Shams, Malihe ^a   Marchet, Aberto ^d   Nardin, Margherita ^a   Pintacuda, Giovanna ^a   Di Maggio, Antonio ^a   Marchesi, Maddalena ^a   Carli, Paolo ^a   Fiduccia, Pasquale ^a   Artioli, Grazia ^a   Nitti, Donato ^d  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c Laboratory of Pharmacology and Molecular Biology   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Placlitaxel; Platinum resistant patients; Platinum sensitive patients; Taxol

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PATIENT SAFETY; PERITONEUM CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CARCINOMA, PAPILLARY; CYSTADENOMA, SEROUS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79551493512     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin, 59: 225-249, 2009.
2. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol, 17: 767-775, 1999.
3. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95 Suppl: S161-192, 2006.
4. Kristensen GB, Trope C: Epithelial ovarian carcinoma. Lancet, 349: 113-117, 1997.
5. Cannistra SA: Cancer of the ovary. N Engl J Med, 351: 2519-2529, 2004.
6. Thigpen T: The if and when of surgical debulking for ovarian carcinoma. N Engl J Med, 351: 2544-2546, 2004.
7. Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S: Distant metastases in epithelial ovarian carcinoma. Cancer, 60: 1561-1566, 1987.
8. Bergman F: Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand, 45: 211-231, 1966.
9. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep, 62: 1-11, 1978.
10. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol, 19: 1901-1905, 2001.
11. McClay EF, Howell SB: A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol, 36: 1-6, 1990.
12. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med, 97: 845-851, 1982.
13. Trimble EL, Christian, MC: National Cancer Institute - United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer, 18 Suppl 1: 26-28, 2008.
14. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 354: 34-43, 2006.
15. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med, 335: 1950-1955, 1996.
16. NCI: NCI Clinical Announcement on Intraperitoneal Chemotherapy in Ovarian cancer (available at http://ctep.cancer.gov/highlights/ovarian.html), 2006 (accessed December 7, 2010).
17. Markman M, Bundy BN, Alberts DS, Jowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol, 19: 1001-1007, 2001.
18. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD: Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep, 67: 1085-1092, 1983.
19. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF: Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol, 20: 1-9, 1985.
20. DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol, 18: 235-238, 1986.
21. Elferink F, van der Vijgh WJ, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol, 21: 57-60, 1988.
22. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani, E, Kohno I: Firstline intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol, 90: 637-643, 2003.
23. Miyagi Y, Fujiwara K. Kigawa J, Itamochi H, Nagao S., Aotani E. Terakawa N, Kohno I: Intraperitoneal carboplatin infusion may be a pharmacologicallymore reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol, 99: 591-596, 2005.
24. Fujiwara K, Markman M, Morgan M, Coleman RL: Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol, 97: 10-15, 2005.
25. Nagao S, Fujiwara K, Ohishi R, Nakanishi Y, Iwasa N, Shimizu M, Goto T, Shimoya, K: Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer, 18: 1210-1214, 2008.
26. Fuiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E: Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecologic cancer study group study. Int J Gynecol Cancer, 19: 834-837, 2009.
27. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G, Ferrazzi E, Perin A, Donach M, Zoli W: Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol, 100: 318-323, 2006.
28. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res, 17: 37-49, 1982.
29. McNair DM, Lorr M, Droppleman LF: Profile of mood states manual. Educational and Industrial Testing Service, San Diego, CA, 1971.
30. Reijneveld SA, Spijker J, Dijkshoorn H: Katz' ADL index assessed functional performance of Turkish, Moroccan, and Dutch elderly. J Clin Epidemiol, 60: 382-388, 2007.
31. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9: 179-186, 1969.
32. Crum RM, Anthony JC, Bassett SS, Folstein MF: Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA, 269: 2386-2391, 1993.
33. WHO Handbook for reporting results of Cancer Treatment. WHO offset publication No. 48, Neoplasma, 20: 37-46, 1980.
34. Franklin HR, Simonetti GP, Dubbelman AC, ten Bokkel Huinink WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB, Aaronson NK: Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol, 5: 113-117, 1994.
35. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45: 228-247, 2009.
36. Mackey JR, Venner, PM: Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol, 6: 474-76, 1996.